AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02101203
Drug: 0.5 mgTestosterone + 10 mg Buspirone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A total of 28 doses will be provided. Subjects are required to take a minimum of 8 doses over the 8-week treatment period (1 dose/week). The other 20 doses may be taken as desired (ie, on demand) throughout the 8-week treatment period; dosing is permitted every 2 days (ie, on alternate days).
Trial: NCT01962831
Drug: Dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02001181
Drug: Placebo ointment (Vehicle)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ointment (vehicle) twice daily (BID) for 4 weeks
Trial: NCT00771316
Drug: MK0826 (ertapenem)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 1.0g IV infused over a 30 minute interval at hour 0
Trial: NCT02027376
Drug: LDE225
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04171284
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg, Q3W, maximum treatment up to six cycles
Trial: NCT01244815
Drug: Rescue medication
RxNorm normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For participants whose symptoms worsen or are not adequately controlled on assigned treatment, rescue medication may be administered during the trial in the following circumstances. For the control of agitation, anxiety, insomnia, restlessness, or akathisia and extrapyramidal symptoms (EPS) some benzodiazepines and EPS medications (i.e., anticholinergics) are allowed. Benadryl (diphenhydramine) and beta blockers are also permitted, provided that they are not taken within 8 hours of efficacy assessments.
Trial: NCT00806338
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00945555
Drug: Antibacterial agent for the treatment of febrile neutropenia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The antibacterial agent used by the investigators for febrile neutropenia will be determined and classified in the preference order
Trial: NCT02612129
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04226547
Drug: Non-Vitamin K Oral Antagonists
RxNorm normalized name: Vitamin K antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initiation or continuation of a NOAC drug
Trial: NCT00704262
Drug: Calcipotriol plus hydrocortisone (LEO 80190)
RxNorm normalized name: hydrocortisone Rectal Cream [Recort Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily application
Trial: NCT03332771
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Trial: NCT03332771
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: capsule~Route of administration: oral
Trial: NCT01039974
Drug: GSK962040
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK962040. Planned doses per cohort as follows:~Cohort 1 planned dose = 10 mg; Cohort 2 to be determined based on data from Cohort 1
Trial: NCT02345278
Drug: SUBLIVAC FIX Mite mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study medication will be taken sublingually once a day. Patients will start with one drop and increase the dose by one drop each consecutive day until the maintenance dose (5 drops/day) is reached. Drops should be kept under the tongue for 2-3 minutes before swallowing. After reaching the maintenance dose patients will be treated up to 1 month.
Trial: NCT04426201
Drug: CYT107
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM administration at 10µg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay
Trial: NCT04426201
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same number, volume and frequency of IM administration of saline
Trial: NCT01043146
Drug: COR-1
RxNorm normalized name: Corticosteroid-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single intravenous administration of 10, 40, 80, 160 or 240 mg of COR-1
Trial: NCT01043146
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous 0.9 % NaCl
Trial: NCT00478881
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vardenafil hydrochloride-matching film-coated tablets BID for oral intake for 6 weeks
Trial: NCT00473473
Drug: Placebo homeopathic remedy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: identical to treatment without active component
Trial: NCT00894023
Drug: Intracoronary bolus wtih ClearWay™RX catheter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary bolus with Clearway catheter
Trial: NCT01854203
Drug: Inductive chemotherapy + IMRT
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT.
Trial: NCT01777347
Drug: 3% Saline
RxNorm normalized name: dextrose 2.5%-0.3% saline (obsolete)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 4 mL nebulization of 3% saline with 20 minutes interval
Trial: NCT00288171
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsule twice daily for one month
Trial: NCT02611960
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral tablet
Trial: NCT00555685
Drug: NaCl 7,5% (Hypertonic Saline Solution)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the intervention arm will receive 100ml of NaCl 7,5, twice daily during 3 days
Trial: NCT00555685
Drug: NaCl 0,9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the placebo arm will receive 100ml of NaCl 0,9% twice daily during 3 days
Trial: NCT04204122
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: -The placebo is artificial tear drops
Trial: NCT00080275
Drug: Niacin Extended-Release and simvastatin Tablets
RxNorm normalized name: niacin / simvastatin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02818556
Drug: Belotero Balance
RxNorm normalized name: Rebalance
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01698320
Drug: Placebo MDPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo MDPI (multi-dose dry powder inhaler) to match the active intervention.
Trial: NCT00359970
Drug: Azithromycin 500 mg
RxNorm normalized name: azithromycin 500 MG
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A single 500 mg dose at the start of treatment
Trial: NCT00359970
Drug: Azithromycin 1000 mg
RxNorm normalized name: azithromycin 1000 MG
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A single 1000 mg dose at the start of treatment
Trial: NCT01189240
Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00518518
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02005432
Drug: panfotocoagulation (PASCAL)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02005432
Drug: panfotocoagulation (PRP) single shoot (ETDRS)
RxNorm normalized name: Toxicodendron pubescens shoot extract
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03126370
Drug: TDF with a boosted protease inhibitor
RxNorm normalized name: Protease inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants who are already taking tenofovir disoproxil fumarate 300 mg (in the form of Viread or Truvada) in combination with either a ritonavir- or cobicistat-boosted protease inhibitor for HIV treatment will continue to take their prescribed treatment for 12 weeks after enrollment.~Other: Blood draws for tenofovir PK, renal function assessment
Trial: NCT03126370
Drug: TAF with a boosted protease inhibitor
RxNorm normalized name: Protease inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be switched from tenofovir disoproxil fumarate to tenofovir alafenamide 25 mg/emtricitabine 200 mg with a boosted protease inhibitor.~Other: Blood draws for tenofovir PK, renal function assessment
Trial: NCT03126370
Drug: TAF with a boosted protease inhibitor and LDV/SOF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After taking tenofovir alafenamide/emtricitabine for 12 weeks, participants will then start taking ledipasvir 90 mg/sofosbuvir 400 mg (Harvoni) in combination with the tenofovir alafenamide 25 mg/emtricitabine 200 mg (Descovy) and a boosted protease inhibitor for 4 weeks. Subjects will then return to taking tenofovir alafenamide 25 mg/emtricitabine 200 mg (Descovy) and a boosted protease inhibitor for the final 12 weeks.~Other: Blood draws for tenofovir PK, renal function assessment
Trial: NCT01264211
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Week 0 to Week 4: Diacerein 50 mg daily for 4 weeks Week 4 to Week 24: Diacerein 100 mg daily for 20 weeks
Trial: NCT02495467
Drug: MED Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At least 4 applications of MED2005 prior to intercourse over a period of 4 weeks
Trial: NCT01008397
Drug: AHIST NDC#58407-012-01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet containing chlorpheniramine tannate 12mg.
Trial: NCT02268955
Drug: IV Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous ibuprofen will be administered for treatment of pain in adults presenting to the ED with biliary colic
Trial: NCT02416583
Drug: Dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01567735
Drug: TMC435
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type=exact number, unit=mg, number=150, form=capsule, route=oral use. TMC435 capsule is taken once daily for 12 weeks.
Trial: NCT00580970
Drug: lovastatin
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The HMG-coA reductase inhibitor used in this study will be lovastatin. Dosage: 20 mg/d PO with evening meal. Patients on a higher dose of lovastatin at the time of study entry may continue at that dose level; for patients switching to lovastatin, the dose will be at the discretion of the prescribing physician, but must be at least 20 mg/day.Schedule: begin on the first day of external beam radiation therapy (external beam alone or external beam followed by brachytherapy) or on the day of brachytherapy (brachytherapy alone or brachytherapy followed by external beam radiotherapy) and continue for 12 months. Patients or their third party payers will be expected to cover the cost of the drug.
Trial: NCT02414451
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered via lactose-filled oral capsule(s) daily for a period of 10 weeks. The schedule of placebo administration will be as follows:~Week 1: 1 capsule, nightly Week 2: 2 capsules, morning \& night Weeks 3 - 8: 3 capsules, morning, afternoon, \& night Week 9: 2 capsules, morning \& night Week 10: 1 capsule, nightly Week 11: no capsules
Trial: NCT04275219
Drug: The Placebo of Tongfu capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Placebo of Tongfu capsules are made from dextrin, starch and so on.
Trial: NCT03985384
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1.5 ml, pen-injector for SC injection.
Trial: NCT00943124
Drug: MK0524B (ER niacin (+) laropiprant (+) simvastatin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of MK0524B (ER niacin 900 mg/ laropiprant 20 mg/ simvastatin 20 mg) in one of two treatment periods.
Trial: NCT00943124
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose simvastatin (Zocor™) 20 mg in one of two treatment periods.
Trial: NCT02185755
Drug: Normal Medication Positive Control
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00730197
Drug: VoSpire® ER Tablets 8 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8mg, single dose fed
Trial: NCT00974766
Drug: Glucocorticoids
RxNorm normalized name: GLUCOCORTICOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 0.5 mg/kg/day for 2 weeks; then 0.5 mg/kg/day for alternate days for eight weeks. Then taper by 5 mg every 2 weeks and discontinue
Trial: NCT00974766
Drug: Glucocorticoids
RxNorm normalized name: GLUCOCORTICOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 0.75 mg/kg/day for 6 weeks; then 0.5 mg/kg/day for 6 weeks. Then taper by 5 mg every 6 weeks and discontinue
Trial: NCT02892123
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Combination therapy with ZW25 - Part 3 Treatment Groups 2 and 5
Trial: NCT00814658
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo three times a day (tid).
Trial: NCT03801733
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Simvastatin
Trial: NCT03801733
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral Rosuvastatin
Trial: NCT03801733
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Pravastatin
Trial: NCT00074438
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral or parenteral repeating dose
Trial: NCT00074438
Drug: corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous repeating dose
Trial: NCT00074438
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous repeating dose
Trial: NCT02713204
Drug: REGN910-3
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02290327
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 ml of 0.9% normal saline
Trial: NCT00810381
Drug: Physiologic saline solution (control substance)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion, infusion period 120 minutes
Trial: NCT01138150
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet of a sugar pill will be given upon subject presentation with an acute migraine attack and after blood levels have been drawn.
Trial: NCT02164773
Drug: 0.9%normal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: use of 1ml of 0.9%normal saline added to 1ml/kg of 0.25% of bupivacaine in the caudal block as placebo to compare with active comparator.
Trial: NCT01424982
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01424982
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01424982
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01424982
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01040221
Drug: Trichuris Suis Ova
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TSO will be administered in vials prepared by Coronado Biosciences. Vials will be diluted with a commercial drink and given to subjects to ingest. Subjects will receive a dose of 2500 ova every two weeks for 12 weeks.
Trial: NCT00903383
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo dosing with daily oral intake for 12 weeks
Trial: NCT02950753
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid bolus or Normal Saline (30ml/kg).
Trial: NCT03624270
Drug: Oral arsenic Trioxide, ATRA and ascorbic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral arsenic trioxide-based frontline induction, consolidation and maintenance will be provided to patients with newly diagnosed acute promyelocytic leukemia.
Trial: NCT02854683
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 liter of intravenous saline will be delivered over 1 hour
Trial: NCT00602667
Drug: Induction Chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive 4 identical cycles of induction chemotherapy including highdose (5 g/m2 or 2.5g/m2 for patients less than or equal to 31 days of age at enrollment) intravenous methotrexate and standard dose vincristine, cisplatin, and cyclophosphamide.
Trial: NCT00602667
Drug: Intermediate-Risk Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction will be followed by consolidation focal radiotherapy (RT) to the tumor bed. Patients less than 12 months old upon completion of induction will receive low risk chemotherapy to delay RT until the age of 12 months. After consolidation, patients will receive 6 cycles of oral maintenance chemotherapy with cyclophosphamide, topotecan, and depending on the diagnosis, either erlotinib or etoposide (VP-16).~Note: The option to receive focal proton beam irradiation was suspended 10/29/2015. Focal photon beam irradiation continues as part of the treatment plan.
Trial: NCT03432286
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SQ
Trial: NCT00468923
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin 10 mg once daily
Trial: NCT01965652
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet taken orally once a day
Trial: NCT00776633
Drug: oral anticoagulation
RxNorm normalized name: monitoring agent for oral anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00140946
Drug: Comparator: placebo / Duration of Treatment: 16 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01488019
Drug: Perforomist-Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo vehicle, 2mL, twice daily for 52 weeks
Trial: NCT01488019
Drug: Perforomist, nebulization, COPD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perforomist, 20 mcg/2 mL, twice daily for 52 weeks
Trial: NCT00756028
Drug: Patients receiving short protocol IVF/ICSI-treatment.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection s.c. Orgalutran® (Ganirelix)0.25 mg once daily from day 5 of FSH-stimulation until HCG-day
Trial: NCT00756028
Drug: Long protocol
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receiving long protocol IVF/ICSI-treatment. Intervention pharmacon: GnRH-agonist (Synarela®:Nafarelin)
Trial: NCT04597762
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone eyedrops
Trial: NCT01536678
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single dose of 600mcg of test formulation of levothyroxine administered in dosing period 1 or 2.
Trial: NCT01536678
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single dose of 600mcg of reference formulation of levothyroxine administered in dosing period 1 or 2.
Trial: NCT03550209
Drug: LCPUFA Oil Supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/kg, 50 mg/kg, or 75 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days
Trial: NCT02362906
Drug: Xiyanping injection
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: ivd. 5 to 10 mg/(kg•d), plus 5% Glucose Injection, 80 to 100 ml, ivd. Once a day injection
Trial: NCT02362906
Drug: wind-heat formula granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: children aged 6 months to 3-year old: 1/2 packet，orally taken two times daily or frequency; children aged 3 to 5-year old: 2/3 packet，orally taken two times daily or frequency; children aged 5 to 14-year old: 1 packet， orally taken two times daily or frequency
Trial: NCT02362906
Drug: phlegm-heat formula granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: children aged 6 months to 3-year old: 1/2 packet，orally taken two times daily or frequency; children aged 3 to 5-year old: 2/3 packet，orally taken two times daily or frequency; children aged 5 to 14-year old: 1 packet， orally taken two times daily or frequency
Trial: NCT02362906
Drug: Fu-xiong San
RxNorm normalized name: fu ling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: external application; 8-10 cm wide, 0.3-0.5 cm thick;10 mins for patient aged 1 to 3-year old; 15 mins for those aged 3 to 5-year old; once daily
Trial: NCT02362906
Drug: second generation cephalosporin
RxNorm normalized name: Second generation cephalosporin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02362906
Drug: Erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ivd. 30 mg/(kg•d), plus 5% Glucose Injection, 80 to 500 ml, ivd. Once a day injection